Abbott Laboratories has received U.S. Food and Drug Administration (FDA) clearance for its Xience V everolimus-eluting coronary stent system.
Xience V was cleared for the treatment of coronary artery disease. It will be launched in the U.S. immediately, according to the Abbott Park, IL-based company.
Related Reading
U.S. panel backs Abbott's drug-coated heart stent, December 3, 2007
Clots low with Abbott stent for 2 yrs: FDA staff, November 28, 2007
Abbott begins stent trial for cardiovascular disease, July 20, 2007
GE, Abbott break off acquisition, July 11, 2007
GE Healthcare to expand once more with $8 billion Abbott deal, January 19, 2007
Copyright © 2008 AuntMinnie.com
